Breast Cancer Treatment Three parts –Local/regional therapy –Systemic therapy –Prevention Weigh risk/benefit ratio Timing Overall impact on survival.

Slides:



Advertisements
Similar presentations
Progress Against Breast Cancer
Advertisements

Ismail Jatoi, MD, PhD, FACS Dale H. Dorn Chair in Surgery Professor and Chief, Division of Surgical Oncology University of Texas Health Science Center.
Pimp Session: Breast By James Lee, MD.
Breast Cancer Systemic Therapy for Early Stage Disease
Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.
Connie Lee, M.D. UF Surgery
BREAST CANCER UPDATE DETECTION TO DIAGNOSIS
The Call (a brief tour of breast cancer) Family Medicine Review Course 2011 Christian Cable, MD, FACP.
Breast Cancer Research in the Developing World Dr. Steven Narod Canada Research Chair in Breast Cancer Boston – November 2009.
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
 Most commonly diagnosed cancer among women in Australia.  Lifetime risk of 1 in 9, risk increases with age.
Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,
Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Ductal Carcinoma in situ
Breast Cancer - the Evidence for Current Management
Partial Breast Irradiation Carol Marquez, M.D. Associate Professor, Department of Radiation Medicine Oregon Health and Sciences University.
Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.
BREAST CANCER 101 BREAST CANCER 101 A REVIEW OF PROBLEMS, DIAGNOSTICS, AND CLINICAL MANAGEMENT Sabha Ganai, MD, PhD Assistant Professor of Surgery Southern.
Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.
WCW Breast Cancer: Early Detection, Diagnosis, Surgical Management 2014 WE CAN AFRICAN SUMMIT September Protea Courtyard Hotel William C. Wood, MD.
Dilemma in management of DCIS
Ductal Carcinoma In Situ (DCIS)
Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.
Investigator Meeting SOFT GOCCHI August 16, 2007 BIGBIG.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #1 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
Breast Cancer Steven Jones, MD. 2 Epidemiology of Breast Cancer 182,460 American women diagnosed each year. 40,480 die each year from the disease Lifetime.
Breast Carcinoma. Anatomy Epidemiology: 10% 17.1/10 28/10 46/ m world wide 6% develop cancer of the breast in their lifetime. 50,000 to 70,000.
First month Second Month First month Second Month Milk line remnant Milk line remnant Accessory axillary breast tissue Accessory axillary breast tissue.
Breast Cancer Methods for Early Detection. Breast Cancer What It Is Methods of Early Detection Risk Factors.
Care Plan Demo Dr Laura Esserman This work is licensed under a Creative Commons Attribution 3.0 Unported License. © 2007 Laura J Esserman.
Breast Cancer: The Profile Ma. Belen E. Tamayo,M.D. Medical Oncologist Makati Medical Center The Medical City.
Radiation Breast Oncology Highlights of SABC 2006 Alison Bevan, MD PhD UCSF Radiation Oncology January, 2007.
Breast Cancer Treatments and their Impact on Quality of Life Kim Arias.
Evidence Based For invasive breast cancer BCT is Tumor excision, axillary node dissection, whole breast radiation Modified mastectomy is total mastectomy.
TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.
Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,
Breast Cancer. Introduction  As old as 1600 BC  Emerges from inner lining of milk ducts  Or the lobules that supply milk  Types:  DCIS  LCIS.
Radical Mastectomy is no longer the standard Improved adjuvant and neoadjuvant therapy Chemotherapy Endocrine therapy Radiation treatment Reconstruction.
Published online July 24, Aromatase inhibitors versus tamoxifen in early breast.
DL Wickerham MD Deputy Chairman NRG Oncology Oct 5, 2015
Neoadjuvant therapy for breast cancer: the Stoddard protocol Scott D. Hamling, MD General Surgeon The Iowa Clinic.
Breast Cancer Treatment: An Evidence-based Review Judith Luce, M.D.
“Big Data, Better Treatment”: The work of the Early Breast Cancer Trialists’ Collaborative Group Rory Collins BHF Professor of Medicine & Epidemiology.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Recent and evolving trends in breast and colon cancer by Jeff Kolbasnik.
BREAST CANCER Oncology
STAR. 2 NSABP P-1 Trial Results: Age > 50 Category TamoxifenPlacebo ARD RR(95% CI) n 4010 IR n 4008 IR Breast Cancer Invasive Invasive Non-invasive Non-invasive
‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.
Treatment Options for Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Ongoing Studies This program is supported by an educational.
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,
BREAST BRACHYTHERAPY OUTCOMES EVALUATION Margaret Pierce DNP, APRN, BC University of Tennessee Knoxville, Tennessee.
How Do We Treat HR positive Breast Cancer in Postmenopausal Women?
The Elliott Breast Center * Baton Rouge, LA *
Breast Cancer Treatment. Treatment 2 aspects 1. Treatment of the breast itself: “Local Treatment” 2. Treatment of the whole body = “Systemic treatment”
The New trends in the Management of Breast Cancer 謝渙發 桃園縣醫師公會監事 怡仁綜合醫院副院長 教育部部定助理教授 國防醫學院外科學系臨床教授.
Breast Surgery in Delhi Breast Cancer Epidemiology Halsted Theory Radical Mastectomy Fisher Theory Modified Radical Mastectomy Goals of Breast Conservation.
BREAST CANCER Anterpreet Neki, MD , MS
Case 3 Jane McNicholas Consultant Oncoplastic Breast Surgeon
Ari Brooks, MD Cancer Surgeon, Big Data End User
Breast Cancer Protocol
Dr Amit Gupta Associate Professor Dept Of Surgery
Thanh Nhan Hospital MALE BREAST CANCER: CASE REPORT
Treatment Overview: The Multidisciplinary Team
Presentation transcript:

Breast Cancer Treatment Three parts –Local/regional therapy –Systemic therapy –Prevention Weigh risk/benefit ratio Timing Overall impact on survival

Local/regional therapy Surgery –Halsted Radical Mastectomy –Modified Radical Mastectomy ( Patey) –Total Mastectomy –Lumpectomy –LumpAx Radiation – reduces LR ½- ¾ and decreases deaths for ¼ recurrences prevented post mastectomy –Whole breast –5 field –Partial breast ( mammosite)

Systemic therapy Prognostic signs –Size, nodes (sentinel vs regular), grade Predictive signs –ER, PR, Ki 67, Her-2, etc. Two major types –Cytotoxic – reduces death rate about 1/3 Antracyline based Taxane based Herceptin enhancement –Hormonal Tamoxifen (SERM) – reduces death rate about 1/4 Aromatase Inhibitors – reduces death rate about 1/3 Ovarian ablation, etc.

Prevention TAM – reduces incidence of new cancers 49% if first ca was ER+ AI’s – reduce incidence of new cancers post-menopausally by 75-78% if first ca was ER+ PMastectomy reduces risk by > 95%

Case 1 47 y.o. WF 1.2 cm IDC detected on annual mammo –MA 11 –PG 31 –Fam hx – 51 –No prior bx –No other lesions in either breast on exam or imaging –No c/o systemic disease –Node negative on exam –No grave signs on exam Local therapy options a)Lumpectomy b)Lumpectomy and Rad c)LumpAx Rad d)TM e)MRM f)HRM g)TM Rad h)MRM Rad i)HRM Rad

Case 1 Path –Margins negative –Nodes negative –ER+ PR+ –Her 2 – –Ki67 18% Systemic Rx a)AC x 4 b)AC x 4 and T x 4 c)Tam x 5 yrs d)AI x 5 yrs e)a+c f)b+c g)d+c And what about prevention?

Case 1 Which order to Rx? a)Surgery, radiation, chemo b)Radiation, chemo, surgery c)Chemo, radiation, surgery d)Chemo, surgery, radiation e)Doesn’t make a difference

Case 2 27 y.o. WF 2.2 cm ILC detected on SBE –MA 9 –PG none –Fam hx – M and 2 Sisters –No prior bx –No other lesions in either breast on exam or imaging –No c/o systemic disease –Node negative on exam –No grave signs on exam Local therapy options a)Lumpectomy b)Lumpectomy and Rad c)LumpAx Rad d)TM e)MRM f)HRM g)TM Rad h)MRM Rad i)HRM Rad

Case 2 Path –Margins negative –Nodes 1/6+ –ER- PR- –Her 2 + –Ki67 48% Systemic Rx a)AC x 4 b)AC x 4 and T x 4 c)Tam x 5 yrs d)AI x 5 yrs e)a+ herceptin f)b+ herceptin g)d+c + herceptin And what about prevention?

Case 2 Which order to Rx? a)Surgery, radiation, chemo b)Radiation, chemo, surgery c)Chemo, radiation, surgery d)Chemo, surgery, radiation e)Doesn’t make a difference

Case 3 53 y.o. WF 0.6 cm IDC with DCIS detected on annual mammo –MA 11 –PG 31 –Fam hx – none –No prior bx –No other lesions in either breast on exam or imaging –No c/o systemic disease –Node negative on exam –No grave signs on exam Local therapy options a)Lumpectomy b)Lumpectomy and Rad c)LumpAx Rad d)TM e)MRM f)HRM g)TM Rad h)MRM Rad i)HRM Rad

Case 3 Path –Margins negative –Nodes negative –ER+ PR+ –Her 2 – –Ki67 18% Systemic Rx a)AC x 4 b)AC x 4 and T x 4 c)Tam x 5 yrs d)AI x 5 yrs e)a+c f)b+c g)d+c And what about prevention?

Case 3 Which order to Rx? a)Surgery, radiation, chemo b)Radiation, chemo, surgery c)Chemo, radiation, surgery d)Chemo, surgery, radiation e)Doesn’t make a difference

Case 4 83 y.o. WF with DCIS detected on annual mammo –MA 11 –PG 22 –Fam hx – none –No prior bx –No other lesions in either breast on exam or imaging –No c/o systemic disease –Node negative on exam –No grave signs on exam Local therapy options a)Lumpectomy b)Lumpectomy and Rad c)LumpAx Rad d)TM e)MRM f)HRM g)TM Rad h)MRM Rad i)HRM Rad

Case 4 Path –Margins negative –Nodes ? –ER+ PR+ –Her 2 – –Ki67 18% Systemic Rx a)AC x 4 b)AC x 4 and T x 4 c)Tam x 5 yrs d)AI x 5 yrs e)a+c f)b+c g)d+c And what about prevention?

Case 4 Which order to Rx? a)Surgery, radiation, chemo b)Radiation, chemo, surgery c)Chemo, radiation, surgery d)Chemo, surgery, radiation e)Doesn’t make a difference

Case 5 53 y.o. WF 6cm IDC with DCIS detected on PE –MA 11 –PG 31 –Fam hx – none –No prior bx –No other lesions in either breast on exam or imaging –No c/o systemic disease –Node positive on exam –Erythema and edema on exam Local therapy options a)Lumpectomy b)Lumpectomy and Rad c)LumpAx Rad d)TM e)MRM f)HRM g)TM Rad h)MRM Rad i)HRM Rad

Case 5 Path –Margins close –Nodes 5/23 + –ER+ PR- –Her 2 = –Ki67 63% Systemic Rx a)AC x 4 b)AC x 4 and T x 4 c)Tam x 5 yrs d)AI x 5 yrs e)a+c f)b+c g)d+c And what about prevention?

Case 5 Which order to Rx? a)Surgery, radiation, chemo b)Radiation, chemo, surgery c)Chemo, radiation, surgery d)Chemo, surgery, radiation e)Doesn’t make a difference

Case 6 53 y.o. WF with LCIS detected on excision of FA –MA 11 –PG 31 –Fam hx – none –No prior bx –No other lesions in either breast on exam or imaging –No c/o systemic disease –Node negative on exam –No grave signs on exam Local therapy options a)Lumpectomy b)Lumpectomy and Rad c)LumpAx Rad d)TM e)MRM f)HRM g)TM Rad h)MRM Rad i)HRM Rad

Case 6 Path –Margins + –Nodes ? Systemic Rx a)AC x 4 b)AC x 4 and T x 4 c)Tam x 5 yrs d)AI x 5 yrs e)a+c f)b+c g)d+c And what about prevention?

Case 7 55 y.o. BF with ADH found on core bx –MA 9 –PG 21 –Fam hx – none –No prior bx –No other lesions in either breast on exam or imaging –No c/o systemic disease –Node negative on exam –No grave signs on exam Local therapy options a)Lumpectomy b)Lumpectomy and Rad c)LumpAx Rad d)TM e)MRM f)HRM g)TM Rad h)MRM Rad i)HRM Rad

Case 7 Path –Margins + –Nodes ? Systemic Rx a)AC x 4 b)AC x 4 and T x 4 c)Tam x 5 yrs d)AI x 5 yrs e)a+c f)b+c g)d+c And what about prevention?